Abstract: The invention relates to an isolated non-naturally occurring protein comprising the amino acid sequence as set forth in SEQ ID NO: 1, and wherein the amino acid in position 8, 47, 209 and/or 354 is substituted by any amino acid different from the amino acid indicated at that position in said sequence SEQ ID NO: 1.

Abstract: The invention relates to a method for coating a textile material, said method comprising the following steps: a) at least one cycle of impregnating the textile material with a sol-gel adhesion formulation, said sol-gel adhesion formulation being free of polycarboxylic acid; b) at least one cycle of drying the impregnated textile material obtained in step a); c) at least one cycle of impregnating the dried textile material obtained in step b) with an omniphobic or hydrophobic sol-gel formulation comprising sulphamic acid, said omniphobic or hydrophobic sol-gel formulation being different from the sol-gel adhesion formulation; d) at least one cycle of drying the impregnated textile material obtained in step c).

Abstract: Enzyme-triggered self-reacting arm compounds and chemical intermediates used for preparing such compounds and uses thereof, specifically in prodrug design and conjugation technologies. A Ligand-Drug-Conjugate (LDC) includes such enzyme-triggered self-reacting arms.

Abstract: The invention relates to a process for nanostructuring the surface of a solid material in order to form a regular pattern of nanostructures on said surface, comprising: irradiating the surface by a plurality of pulse trains (20) of a femtosecond laser beam: each pulse train (20) comprises at least two pulses (21, 22), each pulse has a peak fluence, and a sum of the peak fluences of the pulses of a pulse train is between 10% and 70% of a threshold fluence corresponding to a material ablation threshold for one pulse for said material, two consecutive pulses of a pulse train are separated by a peak-to-peak duration ?T between 500 fs and 150 ps, two consecutive pulse trains are separated by a duration greater than 10 ?T, obtaining a regular pattern of nanostructures on said portion of surface, having a spatial periodicity lower than 130 nm.

Abstract: The present invention relates to an antibody-drug conjugate comprising a monoclonal antibody or an antigen-binding fragment thereof wherein the monoclonal antibody or the antigen-binding fragment thereof binds to Nectin-4 and wherein the drug is an amatoxin, particularly ?-amanitin.

Abstract: A method of manufacturing a composite material including at least one ply integrating at least one electronic element situated at the surface of the ply. Also, materials obtained thereof and devices including such materials. The method includes: a) preparing or providing a first substrate having at least one layer; b) applying at least one electronic element onto a face of the first substrate; c) at least partially impregnating the so-obtained product within an impregnation material to form a matrix incorporating the at least one electronic element and the first substrate; d) preparing or providing an impregnable second substrate, the second substrate being placed on top of the impregnated at least one electronic element so that the at least one electronic element is interposed between the first substrate and the second substrate; e) removing the first substrate from the impregnated product obtained; and f) recovering the composite material.

Abstract: PI3K signalling is the most increased pathway in human cancers. The four isoforms of PI3K are thought to be activated by different redundant mechanisms leading to a common downstream signalling. However, the mutational pattern of PI3K pathway or its level of expression is not sufficient to predict the sensitivity to PI3K inhibitors. By identifying for the first time a phosphopeptide that predict the sensitivity to p110? and/or p110? inhibitors, the inventors provide insight in how to handle heterogeneity of PI3K expression patterns in tumoral samples for the choice of available PI3K-targetting drugs. Accordingly, the present relates to a phosphopeptide characterized by the amino acid sequence as set forth in SEQ ID NO:1 (PGTPSDHQSQEASQFER) wherein the threonine residue at position 3 is phosphorylated.

Abstract: The present invention relates to an antibody -drug conjugate comprising a monoclonal antibody or an antigen-binding fragment thereof wherein the monoclonal antibody or the antigen-binding fragment thereof binds to Nectin-4 and wherein the drug is a topoisomerase I inhibitor, particularly exatecan.

Abstract: A lifetime optimization method for a two-sided photovoltaic module, which includes at least one multi-junction stack, where the stack's first junction layer is on the module's first side, which is exposed to the sun at the beginning of the module's life in the module's base position, and the stack's last junction layer is arranged under the module's second side, which receives diffused and reflected light and light passed through the stack. The method includes measuring the full module's output power (PFM); calculating an estimated output power for the last junction layer (PLL) as a function of the first irradiance in the module's turned over position, where the second side becomes its upper side; comparing the estimated PLL with the PFM when the first side is the upper side and recommending turning over the module when the base position's PFM becomes less than the turned over position's estimated PLL.

Abstract: The present invention relates to humanized antibodies that specifically bind to human BTN3A and their use in treating cancer and infectious disorders.

Abstract: A method may activate a fuel cell including a plurality of electrochemical cells in a stack, the fuel cell being intended to operate, during at least one nominal operating phase, as an electric generator. Such a method may include, during an activation phase by electrolysis, prior to the at least one nominal operating phase: electrically supplying the fuel cell by an external electric generator, the electric supply being configured to apply an activation voltage greater than the voltage of the cell in an open circuit (OCV); fluid supplying a humid gas fluid at a first electrode and/or a second electrodes. The humid gas may have a relative humidity (RH) such that 40%?RH<100%. The fuel cell may operate in electrolysis during the activation phase called by electrolysis.

Abstract: A composition of yeast polysaccharides including ?(1,6)-glucans, preferably also mannans and ?-glucans. The yeast polysaccharides are extracted from yeast cell wall fragments. Typically, the ?-glucans are ?(1,6)-glucans. Also, a method for obtaining such a composition, including at least one step of fractionating a composition of yeast cell walls and extracting an insoluble fraction, and at least one step of extracting a soluble fraction from the insoluble fraction obtained in step a). Further, a composition with a human or veterinary therapeutic objective, for the treatment of gastrointestinal pathologies associated with pathogenic microorganisms, as well as to its non-therapeutic use for improving intestinal comfort.

Abstract: Method for estimating an axial power imbalance in a nuclear reactor, comprising the following steps: obtaining a reactor power setpoint, for each variable of a plurality of variables of the reactor, determining a sequence of the variable, the sequence representing estimated future variations of the variable, determining a sequence of the axial power imbalance, by taking into account the sequences of the plurality of variables of the reactor, the determination of the sequence of the axial power imbalance using a machine learning module that is trained beforehand on historic reactor data.

Abstract: The present invention relates to a virus-derived particle comprising one or more Cas protein(s), as well as to kits and methods using the same for altering a target nucleic acid.

Abstract: The present invention relates to the use of a sequence chosen among Seq ID No 3, Seq ID No 1, Seq ID No 2, Seq ID No 4, Seq ID No 5, Seq ID No 6, Seq ID No 7, Seq ID No 8, and functional variants thereof, as an odorant binding protein (OBP).

Abstract: A device is suitable for revealing spatial variations in polarization of an electromagnetic radiation, in a form of localized temperature variations. The device includes a surface of a carrier which is electrically and thermally insulating, and includes an array of patterns which each consist of at least one rectilinear segment of a sensitive material, of which the orientation is variable within each pattern or between neighboring patterns. Such device may be used with a thermal camera to reveal, in infrared images, temperature variations which are localized at segments not perpendicular to a local direction of linear polarization of the radiation.

Abstract: The present invention relates to a compound of the following general formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, for use as drug for inhibiting ferroptosis.

Abstract: An optical structure comprising at least one stack having a central filter (1) and two sandwiching optical elements (2,3) between which the central filter (1) is interposed, wherein the central filter (1) is in a matrix material. The matrix material being doped with at least one doping agent, the central filter (1) and the two optical elements (2,3) on either side thereof being assembled by bonding layers (4a, 4b) of a material based on the same matrix material as that of the central filter, the optical elements (2,3) on either side of the central filter (1) and the bonding layers (4a, 4b) each having a refractive index equal to that of the material of the central filter or only differing from this refractive index within a range of plus or minus 0.05, preferably within a range of plus or minus 0.02.

Abstract: The invention concerns a method for calibrating a system for real-time measurement of the activity of a cognitive function of a test subject, the method comprising the successive steps of: acquiring electrical signals representative of a neural activity of a test subject; calculating values of markers of the cognitive function activity; generating a plurality of copies of calculated values of markers and adding noise to the generated copies; and, constructing a classifier by machine learning, based on the calculated marker values and noisy copies, the classifier being suitable for measuring the activity of the cognitive function of the test subject by calculating a probability that an electrical signal representative of the neural activity of the test subject results from a predetermined activity state of the cognitive function of the test subject.

Abstract: The present invention relates to a virus-derived particle comprising one or more Cas protein(s), as well as to kits and methods using the same for altering a target nucleic acid.